Busulfan, Melphalan, and Bortezomib Compared to Melphalan as a High Dose Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow Up of a Novel High Dose Regimen

Melphalan at a dose of 200 mg/m(2) (MEL200) remains the standard high dose therapy before autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Intensifying the high dose regimen has shown promising results. We report here 7-year follow up of our novel high dose regimen of busulfan...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leuk Lymphoma
Главные авторы: Hagen, Patrick, D’Souza, Anita, Hari, Parameswaran, Davila, Omar, Zhang, Mei-Jie, Vesole, David H., Smith, Scott E., Rodriguez, Tulio E, Stiff, Patrick J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7786301/
https://ncbi.nlm.nih.gov/pubmed/32865474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1811275
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы